Cencora Elects Frank Clyburn to Its Board of Directors
Cencora, Inc. (NYSE: COR) has announced the election of Frank Clyburn to its Board of Directors, effective October 1, 2024. This addition will increase the board to thirteen members. Mr. Clyburn, a seasoned executive with extensive experience in the pharmaceutical industry, most recently served as CEO and board member of International Flavors and Fragrances Inc. His background includes leadership roles at major pharmaceutical manufacturers, notably as Executive Vice President and President of Human Health at Merck. Cencora's leadership, including Lead Independent Director Mark Durcan and Chairman, President & CEO Steven H. Collis, expressed confidence that Mr. Clyburn's expertise will contribute to the company's long-term growth and pharmaceutical-centric strategy.
Cencora, Inc. (NYSE: COR) ha annunciato l'elezione di Frank Clyburn nel suo Consiglio di Amministrazione, con effetto a partire dal 1 ottobre 2024. Questa aggiunta aumenterà il numero dei membri del consiglio a tredici membri. Il signor Clyburn, un dirigente esperto con una vasta esperienza nel settore farmaceutico, ha recentemente ricoperto il ruolo di CEO e membro del consiglio di International Flavors and Fragrances Inc. Il suo percorso include ruoli di leadership presso importanti produttori farmaceutici, in particolare come Vice Presidente Esecutivo e Presidente della Salute Umana presso Merck. La leadership di Cencora, inclusi il Direttore Indipendente Principale Mark Durcan e il Presidente, CEO e Chairman Steven H. Collis, ha espresso fiducia che l'expertise del signor Clyburn contribuirà alla crescita a lungo termine dell'azienda e alla sua strategia incentrata sui farmaci.
Cencora, Inc. (NYSE: COR) ha anunciado la elección de Frank Clyburn a su Junta Directiva, con efecto a partir del 1 de octubre de 2024. Esta adición aumentará el número de miembros de la junta a trece miembros. El Sr. Clyburn, un ejecutivo experimentado con amplia trayectoria en la industria farmacéutica, se desempeñó recientemente como CEO y miembro de la junta de International Flavors and Fragrances Inc. Su experiencia incluye roles de liderazgo en importantes fabricantes farmacéuticos, notablemente como Vicepresidente Ejecutivo y Presidente de Salud Humana en Merck. La dirección de Cencora, incluidos el Director Independiente Principal Mark Durcan y el Presidente, CEO y Chairman Steven H. Collis, expresó su confianza en que la experiencia del Sr. Clyburn contribuirá al crecimiento a largo plazo de la empresa y a su estrategia centrada en la farmacéutica.
Cencora, Inc. (NYSE: COR)는 Frank Clyburn을 이사회에 선임했다고 발표했습니다. 이 효력은 2024년 10월 1일부터 발효됩니다. 이 추가로 이사회는 13명으로 늘어납니다. Clyburn 씨는 제약 산업에서 광범위한 경험을 가진 베테랑 경영자로서 최근에는 International Flavors and Fragrances Inc.의 CEO 및 이사로 재직했습니다. 그의 경력에는 Merck에서 인류 건강 부사장 및 사장으로서의 주요 제약 제조업체에서의 리더십 역할이 포함됩니다. Cencora의 리더십, 즉 수석 독립 이사 Mark Durcan과 회장 겸 CEO인 Steven H. Collis는 Clyburn 씨의 전문성이 회사의 장기적인 성장과 제약 중심 전략에 기여할 것이라고 확신했습니다.
Cencora, Inc. (NYSE: COR) a annoncé l'élection de Frank Clyburn à son Conseil d'Administration, prenant effet le 1er octobre 2024. Cet ajout portera le nombre de membres du conseil à treize membres. M. Clyburn, un cadre chevronné avec une vaste expérience dans l'industrie pharmaceutique, a récemment été PDG et membre du conseil d'International Flavors and Fragrances Inc. Son parcours inclut des rôles de direction au sein de grands fabricants pharmaceutiques, notamment en tant que Vice-Président Exécutif et Président de la Santé Humaine chez Merck. La direction de Cencora, y compris le Directeur Indépendant Principal Mark Durcan et le Président, PDG et Chairman Steven H. Collis, a exprimé sa confiance que l'expertise de M. Clyburn contribuera à la croissance à long terme de l'entreprise et à sa stratégie centrée sur la pharmacie.
Cencora, Inc. (NYSE: COR) hat die Wahl von Frank Clyburn in seinen Vorstand angekündigt, die am 1. Oktober 2024 in Kraft tritt. Diese Erweiterung wird die Anzahl der Vorstandsmitglieder auf dreizehn Mitglieder erhöhen. Herr Clyburn, ein erfahrener Manager mit umfassender Erfahrung in der Pharmaindustrie, war zuletzt CEO und Vorstandsmitglied von International Flavors and Fragrances Inc. Sein Werdegang umfasst Führungspositionen bei großen Pharmaherstellern, insbesondere als Executive Vice President und Präsident für Human Health bei Merck. Die Führung von Cencora, einschließlich des Hauptunabhängigen Direktors Mark Durcan und des Vorsitzenden, Präsidenten und CEO Steven H. Collis, äußerte das Vertrauen, dass die Expertise von Herrn Clyburn zum langfristigen Wachstum des Unternehmens und zu seiner pharmazeutisch orientierten Strategie beitragen wird.
- Addition of an experienced pharmaceutical industry executive to the board
- Potential for fresh insights and perspectives to support long-term growth strategy
- Expansion of board expertise in line with company's pharmaceutical-centric focus
- None.
“Cencora’s Board of Directors is pleased to welcome Mr. Clyburn as a director. His many years of executive experience, including within the pharmaceutical industry, will be an asset to the company as we continue to focus on long-term, sustainable growth,” said Mark Durcan, Lead Independent Director.
“Frank is a tenured executive leader who will bring valuable insights and perspectives to his role as a member of our Board,” said Steven H. Collis, Chairman, President & Chief Executive Officer. “We look forward to benefiting from his expertise and guidance as we continue to execute against our pharmaceutical-centric strategy.”
Mr. Clyburn recently served as Chief Executive Officer and as a member of the board of directors of International Flavors and Fragrances Inc. Prior to his roles with IFF, Mr. Clyburn spent decades in various leadership roles at leading pharmaceutical manufacturers, including Executive Vice President and President of Human Health at Merck. Mr. Clyburn earned his B.A. from Franklin & Marshall College and an M.B.A. from Arizona State University.
About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #24 on the Global Fortune 500 with more than
View source version on businesswire.com: https://www.businesswire.com/news/home/20240814147025/en/
Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
610-727-3693
bennett.murphy@cencora.com
Source: Cencora
FAQ
When will Frank Clyburn join Cencora's (COR) Board of Directors?
How many members will Cencora's (COR) Board of Directors have after Frank Clyburn's election?
What is Frank Clyburn's most recent executive role before joining Cencora's (COR) board?
What pharmaceutical industry experience does Frank Clyburn bring to Cencora's (COR) board?
